Report Information More information from: https ://www.wis eguyreports .com/reports /495868
Insomnia - Pipeline Review, H1 2016 Report / Search Code: WGR495868
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Ins omnia - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Ins omnia - Pipeline Review, H1 2016’, provides an overview of the Ins omnia pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Ins omnia, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Ins omnia and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Ins omnia - The report reviews pipeline therapeutics for Ins omnia by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Ins omnia therapeutics and enlis ts all their major and minor projects - The report as s es s es Ins omnia therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Ins omnia Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Ins omnia - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Ins omnia pipeline depth and focus of Indication therapeutics
- Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 6 Lis t of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Ins omnia Overview 9 Therapeutics Development 10 Pipeline Products for Ins omnia - Overview 10 Pipeline Products for Ins omnia - Comparative Analys is 11 Ins omnia - Therapeutics under Development by Companies 12 Ins omnia - Therapeutics under Inves tigation by Univers ities /Ins titutes 13 Ins omnia - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Ins omnia - Products under Development by Companies 17 Ins omnia - Products under Inves tigation by Univers ities /Ins titutes 18 Ins omnia - Companies Involved in Therapeutics Development 19 Eis ai Co., Ltd. 19 Evotec AG 20 Grupo Ferrer Internacional, S.A. 21 Heptares Therapeutics Limited 22 Intec Pharma ltd. 23 Intra-Cellular Therapies , Inc. 24 Johns on & Johns on 25 Merck & Co., Inc. 26 Neurim Pharmaceuticals Ltd 27 Novartis AG 28 Reviva Pharmaceuticals Inc. 29 Shionogi & Co., Ltd. 30 Takeda Pharmaceutical Company Limited 31 Ins omnia - Therapeutics As s es s ment 32 As s es s ment by Monotherapy Products 32 As s es s ment by Target 33 As s es s ment by Mechanis m of Action 35 As s es s ment by Route of Adminis tration 37 As s es s ment by Molecule Type 39 Drug Profiles 40 CB-2810 - Drug Profile 40 Product Des cription 40 Mechanis m of Action 40 R& D Progres s 40 Drugs to Inhibit Angiotens in II Receptor Type 1 for Ins omnia - Drug Profile 41 Product Des cription 41 Mechanis m of Action 41 R& D Progres s 41 EVT-201 - Drug Profile 42 Product Des cription 42 Mechanis m of Action 42 R& D Progres s 42 HTL-6641 - Drug Profile 43 Product Des cription 43 Mechanis m of Action 43 R& D Progres s 43 ITI-007 - Drug Profile 44 Product Des cription 44 Mechanis m of Action 44 R& D Progres s 44 JNJ-42847922 - Drug Profile 47 Product Des cription 47 Mechanis m of Action 47 R& D Progres s 47 LASSBio-785 - Drug Profile 49 Product Des cription 49 Mechanis m of Action 49 R& D Progres s 49 LASSBio-786 - Drug Profile 50 Product Des cription 50 Mechanis m of Action 50 R& D Progres s 50
lemborexant - Drug Profile 51 Product Des cription 51 Mechanis m of Action 51 R& D Progres s 51 lorediplon - Drug Profile 52 Product Des cription 52 Mechanis m of Action 52 R& D Progres s 52 MK-8133 - Drug Profile 53 Product Des cription 53 Mechanis m of Action 53 R& D Progres s 53 NEO-1940 - Drug Profile 54 Product Des cription 54 Mechanis m of Action 54 R& D Progres s 54 piromelatine - Drug Profile 55 Product Des cription 55 Mechanis m of Action 55 R& D Progres s 55 ramelteon - Drug Profile 56 Product Des cription 56 Mechanis m of Action 56 R& D Progres s 56 S-117957 - Drug Profile 57 Product Des cription 57 Mechanis m of Action 57 R& D Progres s 57 Small Molecule for Obes ity and Ins omnia - Drug Profile 58 Product Des cription 58 Mechanis m of Action 58 R& D Progres s 58 Small Molecule to Inhibit OX2R for Ins omnia - Drug Profile 59 Product Des cription 59 Mechanis m of Action 59 R& D Progres s 59 UCM-765 - Drug Profile 60 Product Des cription 60 Mechanis m of Action 60 R& D Progres s 60 zaleplon - Drug Profile 61 Product Des cription 61 Mechanis m of Action 61 R& D Progres s 61 zolpidem tartrate - Drug Profile 63 Product Des cription 63 Mechanis m of Action 63 R& D Progres s 63 Ins omnia - Recent Pipeline Updates 64 Ins omnia - Dormant Projects 75 Ins omnia - Dis continued Products 78 Ins omnia - Product Development Miles tones 80 Featured News & Pres s Releas es 80 Feb 01, 2016: Minerva Neuros ciences Announces Top Line Data From MIN-202 Phas e I Clinical Study in Japanes e Patients 80 Jan 11, 2016: Minerva Neuros ciences Announces Favorable Top Line Res ults From MIN-202 Phas e 2A Clinical Trial in Ins omnia Dis order 80 Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Z aleplon in Europe 81 Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous Sys tem Product Candidate MIN-202 81 Sep 24, 2015: Minerva Neuros ciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonis t 82 Jul 14, 2015: Ferrer initiates phas e IIa clinical s tudy of Lorediplon in patients with ins omnia 83 Jun 16, 2015: Minerva Neuros ciences Provides Update on MIN-202, Selective Orexin2 Receptor Antagonis t 83 Jan 21, 2015: Minerva Neuros ciences Reports Pos itive Phas e 1 Data With MIN-202, Selective Orexin-2 Antagonis t for Treatment of Sleep Dis orders Including Primary and Comorbid Ins omnia 84 Dec 10, 2014: Eis ai Demons trates Efficacy Of Inves tigational Dual Orexin Receptor Antagonis t E2006 In Sleep Initiation And Maintenance 85 Sep 22, 2014: Minerva Neuros ciences Announces Completion of FDA Review of Inves tigational New Drug Application for MIN-202 and Plans for Firs t U.S.-Bas ed Clinical Trial 86 Appendix 87 Methodology 87 Coverage 87
Secondary Res earch 87 Primary Res earch 87 Expert Panel Validation 87 Contact Us 87 Dis claimer 88 Lis t of Tables Number of Products under Development for Ins omnia, H1 2016 10 Number of Products under Development for Ins omnia - Comparative Analys is , H1 2016 11 Number of Products under Development by Companies , H1 2016 12 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 13 Comparative Analys is by Late Stage Development, H1 2016 14 Comparative Analys is by Clinical Stage Development, H1 2016 15 Comparative Analys is by Early Stage Development, H1 2016 16 Products under Development by Companies , H1 2016 17 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 18 Ins omnia - Pipeline by Eis ai Co., Ltd., H1 2016 19 Ins omnia - Pipeline by Evotec AG, H1 2016 20 Ins omnia - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 21 Ins omnia - Pipeline by Heptares Therapeutics Limited, H1 2016 22 Ins omnia - Pipeline by Intec Pharma ltd., H1 2016 23 Ins omnia - Pipeline by Intra-Cellular Therapies , Inc., H1 2016 24 Ins omnia - Pipeline by Johns on & Johns on, H1 2016 25 Ins omnia - Pipeline by Merck & Co., Inc., H1 2016 26 Ins omnia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 27 Ins omnia - Pipeline by Novartis AG, H1 2016 28 Ins omnia - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 29 Ins omnia - Pipeline by Shionogi & Co., Ltd., H1 2016 30 Ins omnia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 31 As s es s ment by Monotherapy Products , H1 2016 32 Number of Products by Stage and Target, H1 2016 34 Number of Products by Stage and Mechanis m of Action, H1 2016 36 Number of Products by Stage and Route of Adminis tration, H1 2016 38 Number of Products by Stage and Molecule Type, H1 2016 39 Ins omnia Therapeutics - Recent Pipeline Updates , H1 2016 64 Ins omnia - Dormant Projects , H1 2016 75 Ins omnia - Dormant Projects (Contd..1), H1 2016 76 Ins omnia - Dormant Projects (Contd..2), H1 2016 77 Ins omnia - Dis continued Products , H1 2016 78 Ins omnia - Dis continued Products (Contd..1), H1 2016 79 Lis t of Figures Number of Products under Development for Ins omnia, H1 2016 10 Number of Products under Development for Ins omnia - Comparative Analys is , H1 2016 11 Number of Products under Development by Companies , H1 2016 12 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 13 Comparative Analys is by Late Stage Development, H1 2016 14 Comparative Analys is by Clinical Stage Development, H1 2016 15 Comparative Analys is by Early Stage Products , H1 2016 16 As s es s ment by Monotherapy Products , H1 2016 32 Number of Products by Top 10 Targets , H1 2016 33 Number of Products by Stage and Top 10 Targets , H1 2016 33 Number of Products by Top 10 Mechanis m of Actions , H1 2016 35 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 35 Number of Products by Routes of Adminis tration, H1 2016 37 Number of Products by Stage and Routes of Adminis tration, H1 2016 37 Number of Products by Stage and Top 10 Molecule Types , H1 2016 39
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349